Apellis Pharmaceuticals (APLS) Stock Statistics & Valuation Metrics

Apellis Pharmaceuticals has a market cap or net worth of $2.36B. The enterprise value is $4.03B.

Apellis Pharmaceuticals has 125.52M shares outstanding. The number of shares has decreased by -2.65% in one year.

Apellis Pharmaceuticals’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -33.35%.

The current PE Ratio of Apellis Pharmaceuticals is -19.98. Apellis Pharmaceuticals’s PEG ratio is 0.31.

In the last 12 months, Apellis Pharmaceuticals had revenue of $781.37M and earned -$197.88M in profits. Earnings per share was -$1.59.

In the last 12 months, operating cash flow was -$87.87M and capital expenditures -$403.00K, giving a free cash flow of -$88.27M billion.

Apellis Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of

Apellis Pharmaceuticals upcoming earnings date is May 1, 2025, TBA.

Apellis Pharmaceuticals as a current ratio of 4.25, with Debt / Equity ratio of 2.06

In the past 12 months, Apellis Pharmaceuticals has paid $1.16M in taxes.

Apellis Pharmaceuticals EV to EBITDA ratio is -16.97, with an EV/FCF ratio of -45.46.

Apellis Pharmaceuticals has $411.29M in cash and marketable securities with $469.78M in debt, giving a net cash position of $58.49M billion.

Gross margin is 83.42%, with operating margin of -33.30%, and net profit margin of -27.87%.

The average price target for Apellis Pharmaceuticals is $42.28, which is 11.43% higher than the current price. The consensus rating is Moderate Buy